CBD boosts talk therapy for anxiety? new trial investigates

NCT ID NCT07123467

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing whether adding a low or moderate dose of FDA-approved cannabidiol (Epidiolex) to cognitive behavioral therapy (CBT) helps adults with generalized anxiety disorder more than CBT plus a placebo. Researchers will measure changes in brain activity related to emotion regulation and anxiety symptoms. The trial enrolls 90 adults aged 18-45 who are generally healthy and have a current GAD diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cannabidiol (Epidiolex)
What this could lead to
If successful, this could point toward a new way to boost the effects of talk therapy for anxiety, potentially helping people feel better faster or with fewer sessions.
What could go wrong
This is still an early-stage Phase 3 trial with only 90 participants, so results may not apply to everyone. The improvement in brain activity measured by fMRI may not translate to noticeable real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wayne State University School of Medicine, Tolan Park Medical Building

    RECRUITING

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.